Your browser doesn't support javascript.
loading
Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry.
Caillet Portillo, Damien; Puéchal, Xavier; Masson, Maëva; Kostine, Marie; Michaut, Alexia; Ramon, André; Wendling, Daniel; Costedoat-Chalumeau, Nathalie; Richette, Pascal; Marotte, Hubert; Vix-Portet, Justine; Dubost, Jean-Jacques; Ottaviani, Sébastien; Mouterde, Gaël; Grasland, Anne; Frazier, Aline; Germain, Vincent; Coury, Fabienne; Tournadre, Anne; Soubrier, Martin; Cavalie, Laurent; Brevet, Pauline; Zabraniecki, Laurent; Jamard, Bénédicte; Couture, Guillaume; Arnaud, Laurent; Richez, Christophe; Degboé, Yannick; Ruyssen-Witrand, Adeline; Constantin, Arnaud.
Affiliation
  • Caillet Portillo D; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France. Electronic address: cailletportillo@gmail.com.
  • Puéchal X; National Referral Centre for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Paris, France; Université Paris Cité, Paris, France.
  • Masson M; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France.
  • Kostine M; Department of Rheumatology, National Reference Center for Systemic Autoimmune Rare Diseases RESO, Bordeaux University Hospital, Bordeaux, France.
  • Michaut A; Hospital Centre, Loire Vendée Ocean, Rheumatology, La Roche-sur-Yon, France.
  • Ramon A; Le Bocage Hospital, University Hospital of Dijon, Rheumatology, Dijon, France.
  • Wendling D; CHU de Besançon, Service de Rhumatologie, Université de Franche-Comté, Besançon, France.
  • Costedoat-Chalumeau N; National Referral Centre for Rare Systemic Autoimmune Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Paris, France; Université Paris Cité, Paris, France.
  • Richette P; Hôpital Lariboisière Hospital, AP-HP, Paris, Rheumatology, Paris, France.
  • Marotte H; Université Jean Monnet Saint-Étienne, CHU Saint-Étienne, Service de Rhumatologie, Mines Saint-Etienne, INSERM, SAINBIOSE U1059, F-42023 Saint-Etienne, France.
  • Vix-Portet J; University Hospital of Poitiers, Rheumatology, Poitiers, France.
  • Dubost JJ; CHU Clermont-Ferrand, Université Clermont Auvergne, INRAe, Department of Rheumatology, Clermont Ferrand, France.
  • Ottaviani S; Bichat - Claude-Bernard Hospital, AP-HP, Paris, Rheumatology, Paris, France.
  • Mouterde G; Rheumatology Department, CHU Montpellier & IDESP, Montpellier University, Montpellier, France.
  • Grasland A; Louis-Mourier Hospital, AP-HP, Université Paris Cité, Rheumatology, Colombes, France.
  • Frazier A; Hôpital Lariboisière Hospital, AP-HP, Paris, Rheumatology, Paris, France.
  • Germain V; Pau Hospital, Rheumatology, Pau, France.
  • Coury F; University of Lyon, University Lyon 1, Department of Rheumatology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Immunopathology Federation (LIFe), INSERM UMR 1033, Lyon, France.
  • Tournadre A; CHU Clermont-Ferrand, Université Clermont Auvergne, INRAe, Department of Rheumatology, Clermont Ferrand, France.
  • Soubrier M; CHU Clermont-Ferrand, Université Clermont Auvergne, INRAe, Department of Rheumatology, Clermont Ferrand, France.
  • Cavalie L; Bacteriology and Hygiene Laboratory, Federal Institute of Biology (IFB), Purpan Hospital, Toulouse & IRSD, INSERM, INRAE, ENVT Toulouse III University - Paul Sabatier, Toulouse, France.
  • Brevet P; Department of Rheumatology and CIC-CRB 1404, Inserm 1234, Rouen University, Rouen, France.
  • Zabraniecki L; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France.
  • Jamard B; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France.
  • Couture G; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France.
  • Arnaud L; Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France.
  • Richez C; Department of Rheumatology, National Reference Center for Systemic Autoimmune Rare Diseases RESO, Bordeaux University Hospital, Bordeaux, France.
  • Degboé Y; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France.
  • Ruyssen-Witrand A; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France; Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Team PEPSS "Pharmacologie En Population Cohortes et Biobanques", Toulouse, France.
  • Constantin A; Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France. Electronic address: constantin.a@chu-toulouse.fr.
J Infect ; 88(2): 132-138, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38141787
ABSTRACT

OBJECTIVES:

Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease-modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease.

METHODS:

We initiated a registry including patients with disease-modifying antirheumatic drugs-treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection. We collected clinical, biological, treatment data of the inflammatory rheumatic disease, of Tropheryma whipplei infection, and impact of antibiotics on the evolution of inflammatory rheumatic disease.

RESULTS:

Among 73 inflammatory rheumatic disease patients, disease-modifying antirheumatic drugs initiation triggered extra-articular manifestations in 27% and resulted in stabilisation (51%), worsening (34%), or improvement (15%) of inflammatory rheumatic disease. At the diagnosis of Tropheryma whipplei infection, all patients had rheumatological symptoms (mean age 58 years, median inflammatory rheumatic disease duration 79 months), 84% had extra-rheumatological manifestations, 93% had elevated C-reactive protein, and 86% had hypoalbuminemia. Treatment of Tropheryma whipplei infection consisted mainly of doxycycline plus hydroxychloroquine, leading to remission of Tropheryma whipplei infection in 79% of cases. Antibiotic treatment of Tropheryma whipplei infection was associated with remission of inflammatory rheumatic disease in 93% of cases and enabled disease-modifying antirheumatic drugs and glucocorticoid discontinuation in most cases.

CONCLUSIONS:

Tropheryma whipplei infection should be considered in inflammatory rheumatic disease patients with extra-articular manifestations, elevated C-reactive protein, and/or hypoalbuminemia before disease-modifying antirheumatic drugs initiation or in inflammatory rheumatic disease patients with an inadequate response to one or more disease-modifying antirheumatic drugs. Positive results of screening and diagnostic tests for Tropheryma whipplei infection involve antibiotic treatment, which is associated with complete recovery of Tropheryma whipplei infection and rapid remission of inflammatory rheumatic disease, allowing disease-modifying antirheumatic drugs and glucocorticoid discontinuation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / Hypoalbuminemia / Whipple Disease Limits: Humans / Middle aged Language: En Journal: J Infect Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / Hypoalbuminemia / Whipple Disease Limits: Humans / Middle aged Language: En Journal: J Infect Year: 2024 Document type: Article